Major trial launches for aggressive stomach cancers
NCT ID NCT06093425
Summary
This study is testing whether adding an experimental drug called TST001 to standard chemotherapy and immunotherapy helps people with advanced stomach or gastroesophageal cancer live longer without their cancer getting worse. The trial will involve 820 adults with a specific tumor marker called Claudin18.2 who haven't had prior treatment for their advanced cancer. Participants will be randomly assigned to receive either the new three-drug combination or the current standard two-drug treatment to compare their effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.